Moussa B.H. Youdim
Suchen Sie unter den Mitgliedern der Leopoldina nach Expertinnen und Experten zu Fachgebieten oder Forschungsthemen.
From 1977 to 1994, Moussa Youdim was Chairman and Professor of Pharmacology and Finkelstein Professor of Life Sciences at the Technion-Rappaport Family Faculty of Medicine, Haifa, Israel. Presently he is Professor Emeritus and the Director of the Eve Topf and National Parkinson Foundation, USA, Centers of Excellence for Neurodegenerative Diseases at Technion. He holds the position Distinguished Chair Professor at Yonsei University in Seoul, South Korea.
He received his Ph.D. (1966) at McGill University in Montreal, Canada. The topic of his doctoral thesis was purification and characterization of mitochondrial monoamine oxidase, MAO, in the liver and brain, where he identified for the first time two forms of MAO. Between 1966 and 1971 he was a Welcome Trust Fellow at the University of London Post Graduate School, UK and spent a year at Cambridge University, UK and College de France in Paris, France. Between 1973 and 1977 he was a member of MRC Clinical Pharmacology and Department of Medicine at Oxford University, UK. Youdim, together with Peter Riederer, discovered the first selective MAO B inhibitor as anti-Parkinson drug. During the same periode he was the first person to study the role of iron deficiency or excess on brain function.
At Technion he discovered the anti-Parkinson drug Azilect and anti-Alzheimer drug ladostigil and a whole series of iron chelators as neuroprotective and neurorestorative drugs for the treatment of neurodegenerative diseases. In 2000, his group was the first to employ transcriptomics and proteomic profiling of substantia nigra pars compacta of sporadic Parkinsonian subjects at autopsy and its animal models.
06108 Halle (Saale)
|Tel.||0345 - 47 239 - 120|
|Fax||0345 - 47 239 - 139|